MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

A

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

A

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

A

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

A

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

A

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

Search

Kura Oncology Inc

Geschlossen

BrancheGesundheitswesen

6.34 0.79

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

6.17

Max

6.34

Schlüsselkennzahlen

By Trading Economics

Einkommen

-38M

-57M

Verkäufe

-40M

14M

Gewinnspanne

-407.067

Angestellte

192

EBITDA

-48M

-65M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+314.01% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

7. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-34M

492M

Vorheriger Eröffnungskurs

5.55

Vorheriger Schlusskurs

6.34

Nachrichtenstimmung

By Acuity

50%

50%

148 / 376 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Kura Oncology Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

14. Juli 2025, 22:07 UTC

Wichtige Markttreiber

Trade Desk Rises on S&P 500 Inclusion

14. Juli 2025, 17:06 UTC

Wichtige Markttreiber

Crypto Assets Rally Ahead of Possible U.S. Legislation

14. Juli 2025, 16:47 UTC

Akquisitionen, Fusionen, Übernahmen

NatWest to Sell Stake in Permanent TSB

14. Juli 2025, 23:46 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

14. Juli 2025, 23:38 UTC

Market Talk

Gold Edges Higher Ahead of U.S. CPI Data -- Market Talk

14. Juli 2025, 23:37 UTC

Market Talk

ANZ's Institutional Earnings Likely to Weigh on Outlook -- Market Talk

14. Juli 2025, 23:29 UTC

Market Talk

South32 Bull Eyes Possible Last-Minute Power Deal for Mozal -- Market Talk

14. Juli 2025, 23:29 UTC

Market Talk

Global Energy Roundup: Market Talk

14. Juli 2025, 23:02 UTC

Ergebnisse

China Vanke: Additional Provision for Asset Impairment Also Among Factors Weighing on Results >000002.SZ

14. Juli 2025, 23:02 UTC

Ergebnisse

China Vanke: Weakness in Overall China Real-Estate Sector Weighed on Results >000002.SZ

14. Juli 2025, 23:02 UTC

Ergebnisse

China Vanke 1H Loss Was CNY9.85B >000002.SZ

14. Juli 2025, 23:01 UTC

Ergebnisse

China Vanke Sees 1H Loss CNY10.0B-Loss CNY12.0B >000002.SZ

14. Juli 2025, 23:01 UTC

Ergebnisse

China Vanke Expects 1H Loss to Widen >000002.SZ

14. Juli 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

14. Juli 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

14. Juli 2025, 20:07 UTC

Market Talk

Cloud Computing Giants Will Be the Winner from Software's Loss -- Market Talk

14. Juli 2025, 20:05 UTC

Market Talk

Adobe and Salesforce May Struggle to Keep Up With AI Agents -- Market Talk

14. Juli 2025, 19:11 UTC

Market Talk

Oil Retreats Despite Trump Threats of Russia Sanctions -- Market Talk

14. Juli 2025, 19:09 UTC

Market Talk

Gold Breaks a 3-Day Win Streak -- Market Talk

14. Juli 2025, 18:59 UTC

Market Talk

Hotter Weather Outlook, LNG Flows Boost U.S. Natural Gas -- Market Talk

14. Juli 2025, 18:30 UTC

Akquisitionen, Fusionen, Übernahmen

Synopsys Buy of Ansys Gets China OK. The $35 Billion Deal Is Set to Close. -- Barrons.com

14. Juli 2025, 18:25 UTC

Market Talk

Dollar Gains, Treasury Yields Lose Steam as Trump Threatens Russia -- Market Talk

14. Juli 2025, 18:25 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14. Juli 2025, 16:59 UTC

Market Talk

Goldman Sachs Lifts 2H25 Crude Price Views -- Market Talk

14. Juli 2025, 16:53 UTC

Heiße Aktien

Stocks to Watch Monday: Kenvue, Tesla, Synopsys, Robinhood -- WSJ

14. Juli 2025, 16:27 UTC

Market Talk

Oil Falls as Investors Monitor U.S.-EU Trade, Trump's Russia Sanction Threats -- Market Talk

14. Juli 2025, 16:20 UTC

Market Talk
Ergebnisse

Auto & Transport Roundup: Market Talk

14. Juli 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

14. Juli 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

14. Juli 2025, 16:12 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

Peer-Vergleich

Kursveränderung

Kura Oncology Inc Prognose

Kursziel

By TipRanks

314.01% Vorteil

12-Monats-Prognose

Durchschnitt 26 USD  314.01%

Hoch 40 USD

Tief 8 USD

Basierend auf 13 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Kura Oncology Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

13 ratings

11

Buy

2

Halten

0

Sell

Technischer Score

By Trading Central

5.575 / 6.6Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

148 / 376 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.